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Abstract Hypertension is well established as a risk factor
for the development of atherosclerosis. Data on the impact of
hypertension in patients with ST elevation myocardial
infarction are so far inconsistent, and are mainly related to
studies performed in the thrombolytic era. We assessed the
impact of hypertension over the short and long term in 560
patients with ST elevation myocardial infarction (STEMI)
and without previously known diabetes, all of whom were
submitted to mechanical revascularization and consecu-
tively admitted to our Intensive Cardiac Care Unit. Hyper-
tensive patients were older (p \ 0.001), more frequently
male (0.005), and they showed a reduced eGFR (p \ 0.001).
Smoking was more frequent in nonhypertensive patients
(p \ 0.001), while the incidence of three-vessel coronary
artery disease was higher in hypertensive patients
(p = 0.003). No difference in the in-hospital mortality rates
for the two subgroups was detected. At follow-up (median
32.5 months, 25th–75th percentile 16.9–47.3 months),
Kaplan–Meier survival analysis detected no differences in
mortality between hypertensive and nonhypertensive
patients (log rank v2 0.38, p = 0.538). According to our data,
obtained from a large series of consecutive STEMI patients
without previously known diabetes, all of whom were sub-
mitted to primary PCI, a history of hypertension does not
affect mortality over either the short or the long term.
Moreover, hypertensive patients showed an altered glucose
response to stress, as indicated by higher admission glucose
values, poorer in-hospital glucose control, and a higher
incidence of acute insulin resistance (as indicated by the
HOMA index). Hypertensive patients therefore appear to
warrant careful metabolic management during their hospital
courses.
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Introduction
Hypertension is well established as a risk factor for the
development of atherosclerosis [1–3], and for increased
incidence of cerebrovascular disease [4] and coronary
artery disease [5]. In the INTERHEART study, the strength
of the association of hypertension with risk of first myo-
cardial infarction (MI) was greater in women than in men
[6]. Hypertension is also an important risk factor for death
and ischemic events after presentation with acute coronary
syndromes (ACS) [7].
In the SYMPHONY study [8], which assessed sex-
related differences in the prevalence and treatment of
hypertension among patients presenting with ACS, hyper-
tension was more prevalent in women than in men, while
mortality did not show any gender-related difference.
Data on the impact of hypertension in patients with ST
elevation myocardial infarction (STEMI) are so far
inconsistent, and are mainly related to studies performed in
the thrombolytic era [7, 9–13].
The present investigation was therefore aimed at
assessing the impact of hypertension over the short and
long term in 560 patients with STEMI and without previ-
ously known diabetes, all of whom were submitted to
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mechanical revascularization and consecutively admitted
to our Intensive Cardiac Care Unit (ICCU).
Methods
Study population
From 1 January 2008 to 30 June 2010, 560 consecutive
patients with STEMI (within 12 h from the onset of
symptoms) but without previously known diabetes were
admitted to our ICCU, which is located at a tertiary center.
In our hospital, in Florence, the reperfusion strategy of
STEMI patients is represented by primary PCI [14–19].
STEMI patients are first evaluated by the Medical Emer-
gency System staff in the prehospital setting and then
directly admitted to the catheterization laboratory or
transferred to it after rapid stabilization in First Aid. After
primary PCI, they are admitted to our ICCU. Patients were
defined as hypertensive if they had a known history of
hypertension or were being treated with antihypertensive
medication at the time of the qualifying event [8].
A successful procedure was defined as an infarct artery
stenosis\20% associated with thrombolysis in myocardial
infarction (TIMI) grade 3 flow; TIMI grade 0 to 2 flow,
regardless of the residual stenosis, was regarded as
unsuccessful PCI [20].
The diagnosis of STEMI was based on the criteria of the
American College of Cardiology/American Heart Associ-
ation [20, 21].
On ICCU admission, after PCI, the following parame-
ters were measured in a fasting blood sample: glucose
(mg/dl), insulin values (mIU/l) [15, 17], glycated hemoglobin
(HbA1c, %), troponin I (ng/ml), C-reactive protein (mg/dl)
(normal values \9), alanine aminotransferase (ALT, UI/l),
aspartate amino transferase (AST, UI/l) [22], NT-pro brain
natriuretic peptide (NT-pro BNP) (pg/ml) [18], total cho-
lesterol (mg/dl), triglycerides (mg/dl), HDL (mg/dl), LDL
(mg/dl), and fibrinogen (mg/dl). Creatinine (mg/dl) was
also measured in order to calculate the glomerular filtration
rate (eGFR, ml/min/1.73 m2, MDRD formula) [23]. Glu-
cose and Tn I were measured three times a day during the
ICCU stay, and peak values for each variable were con-
sidered. Glucose measured at discharge was also consid-
ered. Intensive insulin therapy was administered in patients
with significant hyperglycemia (that is, plasma glucose
[180 mg/dl) [24].
Definition of insulin resistance
Criteria used for the definition of insulin resistance are in
accordance with the recently published guidelines pro-
posed by the European Group for the Study of Insulin
Resistance (EGIR). HOMA was calculated according to the
following formula: {[fasting insulin (microU/ml)] 9 [fasting
glucose (mmol/l)]}/22.5. Subjects whose values exceeded
the sex-specific 75th percentile (i.e., 1.80 for women and
2.12 for men) were considered to have insulin resistance
(HOMA-IR) [17, 25–27].
Transthoracic two-dimensional echocardiography was
performed in order to measure left ventricular ejection
fraction (LVEF) on ICCU admission and at discharge.
The study protocol was in accordance with the Decla-
ration of Helsinki and approved by the local ethics com-
mittee. Informed consent was obtained in all patients
before enrollment.
Statistical analysis
Analysis was performed using SPSS 13.0 statistical pack-
age (SPSS Inc., Chicago, IL, USA). Categorical data are
expressed as frequencies and percentages; continuous data
are reported as the mean ± SD or the median (25th–75th
percentile [IR]), depending on whether the distribution is
normal or not. Data have been analyzed by means of v2 (or
Fisher’s exact test when the expected count in a cell was
\5) for categorical data and Student’s t test or the Mann–
Whitney U test for continuous data, according to the shape
of their distribution. When v2 was calculated in a table with
[2 9 2 cells, the differences between the cells were
assessed with the Z-score. Logistic regression analysis was
performed in order to identify predictor(s) of in-hospital
mortality; variables for inclusion were chosen carefully
among those considered clinically relevant and those which
showed a univariate relationship with in-hospital death,
given the number of events available, to ensure parsimony
of the final models. Taking into account the number of
deaths, a bivariate analysis was performed. Candidate
variable(s) that were non-normally distributed were entered
as their log-transformed values. The Hosmer–Lemeshow
goodness-of-fit test and Nagelkerke’s R2 have been repor-
ted. We used Kaplan–Meier survival analysis to assess
differences (if any) in death at follow-up between hyper-
tensive and nonhypertensive patients; results of the logrank
test are reported. A p value \0.05 was considered statis-
tically significant.
Results
Our population comprises 300 STEMI patients with
hypertension (53.6%) and 260 patients without a history of
hypertension (46.4%) (Table 1). Hypertensive patients
were older (p \ 0.001), more frequently male (p B 0.005),
and they showed a reduced eGFR (p \ 0.001) and a higher
BMI (p = 0.025). Smoking was more frequent in
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nonhypertensive patients (p B 0.001). No difference was
observed in door-to-balloon time and in Killip class
between the two subgroups. Mortality rates over the short
and long term did not differ between the two subgroups.
Table 2 shows the angiographic data. No difference in
AMI location was detectable between hypertensive and
nonhypertensive STEMI patients. The incidence of three-
vessel coronary artery disease was higher in hypertensive
patients (p = 0.003). Left ventricular ejection fraction
(both on admission and at discharge) did not differ between
the two subgroups.
As depicted in Table 3, hypertensive STEMI patients
showed lower eGFR (p \ 0.001), higher values of both
admission and peak glycemia (p \ 0.001 and p \ 0.001,
respectively) and of glycated hemoglobin (p = 0.006), and
a higher incidence of HOMA positivity (p = 0.015). The
percentage of patients with glycated Hb C6.5% was higher
in the hypertensive group (p = 0.047). Higher levels of
NT-pro BNP (p B 0.001) and uric acid (p B 0.001),
fibrinogen (p = 0.024), total cholesterol (p = 0.028) and
LDL (p = 0.024) were observed in hypertensive patients.
After excluding patients with HbA1c C6.5% (n = 103,
18.4%), higher values of admission glycemia [nonhyper-
tensive 120 (108–146); hypertensive 132 (114–162) mg/dl;
p = 0.002] and peak glycemia [nonhypertensive 139
(122–166); hypertensive 151 (129–190) mg/dl; p = 0.001]
were observed in STEMI patients with hypertension,
whereas no significant differences were detectable between
the two subgroups in terms of insulinemia [nonhyperten-
sive 8.2 (5.5–13.6); hypertensive 8.2 (5.4–15.9) mIU/l] and
the incidence of HOMA index positivity (nonhypertensive
51.3%, hypertensive 60.0%).
Table 4 shows medications on admission and at dis-
charge in both hypertensive and nonhypertensive patients.
Table 1 Clinical characteristics
of the 560 nondiabetic patients
with ST elevation myocardial
infarction included in the study
Values are frequencies
(percentages), mean ± SD or
median (25th–75th percentile)
Pct percentile, BMI body mass
index, COPD chronic
obstructive pulmonary disease,
PCI percutaneous coronary
intervention, MI myocardial
infarction
Hypertensive patients
(n = 300, 53.6%)
Nonhypertensive patients
(n = 260, 46.4%)
p value
Age (years) 70.1 ± 11.2 62.2 ± 13.2 \0.001
Males/females n (%) 200/100 (66.7/33.3) 201/59 (77.3/22.7) 0.005
BMI (kg/m2) 26.1 (23.8–28.9) 25.5 (23.5–27.7) 0.025
History of n (%)
Smoking 168 (56.0) 188 (72.3) \0.001
COPD 30 (10.0) 18 (6.9) 0.195
Previous PCI 47 (15.7) 29 (11.2) 0.120
Previous MI 50 (16.7) 31 (11.9) 0.111
Symptom to balloon time (min) 234 (160–350) 200 (150–300) 0.053
Killip class n (%)
I–II 268 (89.3) 238 (91.5) 0.378
III–IV 32 (10.7) 22 (8.5)
In-hospital mortality n (%) 8 (2.7) 10 (3.8) 0.430
Follow-up mortality n (%) 42 (14.4) 32 (12.9) 0.594
Table 2 Angiographic
characteristics of the 560
nondiabetic patients with ST
elevation myocardial infarction
included in the study
Values are frequencies
(percentages), mean ± SD or
median (25th–75th percentile)
AMI acute myocardial
infarction, CABG coronary
artery bypass graft,
PCI percutaneous coronary
intervention, EF ejection
fraction
§ Fisher’s exact test. Z score
p \ 0.05
Hypertensive patients
(n = 300, 53.6%)
Nonhypertensive patients
(n = 260, 46.4%)
p value
AMI location n (%)
Anterior 150 (50.0) 142 (54.6) 0.255
Inferior 124 (41.3) 104 (40.0)
Other 26 (8.7) 14 (5.4)
Coronary artery disease n (%)
1-vessel 108 (36.0) 113 (43.5) 0.003
2-vessel 90 (30.0) 92 (35.4)
3-vessel 102 (34.0)§ 55 (21.2)§
Left main n (%) 20 (6.7) 15 (5.8) 0.648
CABG n (%) 6 (2.8) 1 (0.4) 0.085§
PCI failure n (%) 16 (5.4) 19 (7.4) 0.350
Admission EF (%) 42.6 ± 9.2 43.9 ± 9.8 0.100
Discharge EF (%) 43.9 ± 8.5 45.3 ± 8.6 0.068
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On admission and at discharge, hypertensive STEMI
patients were more often on diuretics.
The logistic regression analysis indicated that, in the
overall population, admission EF (1% increase; OR 0.906,
95% CI 0.859–0.956, p \ 0.001) and peak glycemia
(10 mg/dl increase; OR 1.113, 95% CI 1.049–1.181,
p B 0.001) were independent predictors of in-hospital
mortality (Hosmer–Lemeshow v2 8.3, p = 0.407; Nage-
lkerke’s R2 0.28).
At follow-up (median 32.5 months, 25th–75th percentile
16.9–47.3 months), Kaplan–Meier survival analysis
detected no differences in mortality between hypertensive
and nonhypertensive patients (logrank v2 0.38, p = 0.538)
(Fig. 1).
Table 3 Comparison of
laboratory data between
hypertensive and
nonhypertensive patients
Values are frequencies
(percentages), mean ± SD or
median (25th–75th percentile)
GFR glomerular filtration rate,
HOMA homeostatic model
assessment, AST aspartate
transferase, ALT alanine
transferase, Tn troponin,
NT-po BNP N-terminal pro-
brain natriuretic peptide,
ESR erythrocyte sedimentation
rate, CRP C-reactive protein,
HDL high-density lipoprotein,
LDL low-density lipoprotein
Hypertensive patients
(n = 300, 53.6%)
Nonhypertensive patients
(n = 260, 46.4%)
p value
Estimated GFR (ml/min/1.73 m2) 76.3 ± 28.9 88.9 ± 27.5 \0.001
Admission glucose (mg/dl) 144 (118–197) 126 (110–156) \0.001
Peak glucose (mg/dl) 167 (135–224) 145 (125–185) \0.001
Insulinemia (mUI/l) 10.5 (5.8–20.0) 9.0 (5.5–15.6) 0.111
Glycated hemoglobin (%) 6.0 (5.7–6.6) 5.9 (5.5–6.3) 0.006
Glycated hemoglobin C6.5%, n (%) 65 (21.7) 38 (14.6) 0.047
HOMA positivity n (%) 57 (19.0) 30 (11.5) 0.015
AST (UI/l) 67 (66–144) 71 (34–177) 0.456
ALT (UI/l) 40 (25–74) 40 (25–75) 0.906
Peak Tn I (ng/ml) 103.5 (39.9–226.1) 89.0 (46.7–165.9) 0.449
NT-proBNP (pg/ml) 1721 (684–4448) 1066 (362–2504) \0.001
Uric acid (mg/dl) 6.0 ± 1.5 5.4 ± 1.7 \0.001
ESR (mm/h) 26 (14–40) 20 (12–36) 0.078
CRP (mg/dl) 11.0 (9.0–37.0) 10.0 (8.0–23.0) 0.100
CRP positivity n (%) 155 (55.8) 137 (54.4) 0.748
Leucocytes (9103/ll) 10.6 (8.7–13.3) 11.0 (9.0–14.0) 0.326
Fibrinogen (mg/dl) 409 (353–501) 389 (330–473) 0.024
Total cholesterol (mg/dl) 183 ± 45 192 ± 45 0.028
HDL cholesterol (mg/dl) 40 (35–47) 41 (35–48) 0.581
LDL cholesterol (mg/dl) 118 ± 38 125 ± 37 0.024
Triglycerides (mg/dl) 102 (75–140) 102 (78–140) 0.612
Table 4 Medications in
hypertensive and
nonhypertensive patients on
admission and at discharge
Values are frequencies
(percentages)
ACEi angiotensin-converting
enzyme inhibitors,
ARB angiotensin receptor
blockers, ASA acetylsalicylic
acid
Hypertensive
(n = 300, 53.6%)
Nonhypertensive
(n = 260, 46.4%)
p value
Admission n (%)
b-blockers 260 (86.7) 232 (89.2) 0.354
ACEi-ARB 273 (91.0) 232 (89.2) 0.483
Calcium channel
blockers
19 (6.3) 7 (2.7) 0.041
Diuretics 248 (82.7) 189 (72.7) 0.004
ASA 289 (96.3) 251 (96.5) 0.896
At discharge n (%)
b-blockers 254 (84.7) 219 (84.2) 0.887
ACEi-ARB 263 (87.7) 218 (83.8) 0.195
Calcium channel
blockers
12 (4.0) 4 (1.5) 0.081
Diuretics 197 (65.7) 125 (48.1) \0.001
ASA 281 (93.7) 238 (91.5) 0.335
Clopidogrel 286 (95.3) 247 (95.0) 0.854
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Discussion
The main finding of the present investigation, performed in
consecutive hypertensive STEMI patients without previ-
ously known diabetes, all of whom were submitted to PCI,
is that history of hypertension is not able to affect mortality
over both the short and long term. Hypertensive patients
were older and exhibited an altered glucose response to
stress, as indicated by higher admission glycemic values,
poor in-hospital glycemic control (as inferred by peak
glycemia) and a higher incidence of insulin resistance (as
indicated by HOMA index positivity).
In our series, the prevalence of a history of hypertension
was comparable to that reported in previous studies [8, 28,
29], being detectable in half of the population. Moreover,
as previously described [8, 28, 29], in our study, hyper-
tensive patients were older and exhibited reduced renal
function (as inferred by eGFR). Interestingly, unlike the
GREECS study [30], no significant difference in time to
presentation was observed between hypertensive and non-
hypertensive patients. In regard to medications, like pre-
vious reports, no significant difference was observed
between hypertensive and nonhypertensive patients at both
admission and discharge, apart from the increased use of
diuretics in hypertensives.
Available data on the effects of hypertension on mor-
tality in STEMI are so far inconsistent.
In the thrombolytic era, Rabkin et al. [9] showed adverse
short- and long-term outcomes in hypertensive patients. In
the GISSI-2 study, in-hospital and 6-month mortality in
hypertensive MI patients was significantly higher than for
normotensives [10], as was the rate of left ventricular
failure, recurrent angina and recurrent MI. In contrast,
elevated blood pressure was not an independent prognostic
factor for 30-day mortality among MI patients in the
GUSTO-1 study [8]. Nevertheless, patients with very high
blood pressure were excluded from the GUSTO-1 study
due to the use of thrombolytic treatment (though systolic
blood pressure exceeded 180 mmHg in 602 patients).
Ayward et al. [11], evaluating all patients participating in
the GUSTO-1 study, observed that the risk of an early
death was higher in patients with elevated systolic BP. In a
study by Majahalme et al. [12], in-hospital and 6-month
mortality were both similar in hypertensive and normo-
tensive ACS patients, while the rates of recurrent angina,
paroxysmal atrial fibrillation and acute renal failure were
higher among hypertensives. Jonas et al. [13] analyzed
three groups of patients admitted due to MI (with normal,
high normal or elevated BP), and found no significant
differences in in-hospital mortality (5% among normoten-
sives, 4% in patients with high normal BP, and 1.9% among
hypertensives).
In the era of mechanical revascularization, data on this
topic are scarce and conflicting, and have mainly been
reported from small observational studies.
Abrignani and colleagues [30] observed that hyper-
tensive subjects with first AMI have a better in-hospital
outcome than age- and gender-matched normotensive
subjects, perhaps due to a less severe extension of the
infarction area or to a different pathophysiological mech-
anism. On the other hand, according to a recent paper by
Rembeck [28] regarding 366 STEMI patients who were
submitted to mechanical revascularization, no difference
was observed in in-hospital mortality between hypertensive
and normotensive patients.
In our series, comprising a larger group of consecutive
STEMI patients without previously known diabetes, we
confirmed that early mortality rates did not differ between
hypertensive and normotensive patients. Furthermore, we
observed that hypertensive patients exhibited an altered
glycemic response to stress, as indicated by increased
values of admission and peak glycemia and a higher inci-
dence of acute insulin resistance (as indicated by the
HOMA index). This phenomenon can be related to three
main contributory factors. First, the older ages of the
hypertensive patients. In a recent paper [27], we docu-
mented that during the early phase of STEMI, the acute
glucose response to myocardial injury differs according to
age, since older patients showed the highest glucose levels
and the poorest glycemic control during their ICCU stay.
Second, the higher incidence of acute insulin resistance (as
indicated by HOMA positivity) observed in hypertensive
patients may be related to higher BMI, since insulin
secretion in the acute phase of STEMI seems to be strictly
related to BMI [32]. Third, the percentage of patients with
Fig. 1 Kaplan–Meier survival curves in hypertensive and nonhyper-
tensive patients
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glycated hemoglobin C6.5% was higher in the hyperten-
sive group, thus indicating a higher number of patients with
poor glycemic control in the previous months. Interest-
ingly, after excluding patients with glycated Hb C6.5%, the
hypertensive patients still showed increased values of
admission and peak glycemia.
Finally, we observed, for the first time, that hypertensive
STEMI patients without previously known diabetes who
were submitted to primary PCI exhibit a comparable sur-
vival rate at long-term follow-up to that of nonhypertensive
STEMI patients. This can probably be related to the fact
that hypertensive STEMI patients did not show a larger
infarct size or a higher incidence of unsuccessful PCI, and
that medications administered at discharge did not sub-
stantially differ between the two subgroups.
In conclusion, in the era of mechanical revasculariza-
tion, we observed that the mortality rates over both the
short and long term in a large series of consecutive non-
diabetic STEMI patients did not differ between hyperten-
sive and normotensive patients. Moreover, hypertensive
patients showed an altered glucose response to stress,
as indicated by higher admission glucose values, poorer
in-hospital glucose control (as inferred from peak glycemia),
and a higher incidence of acute insulin resistance (as
indicated by the HOMA index). Hypertensive patients
seem therefore to warrant careful metabolic management
during their hospital courses.
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